Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Prothiucil; Belgium: Propylthiouracile; Bulgaria: Propycil; Czech Republic: Propycil; Denmark: Propyltiouracil; Estonia: Tiotil; France: Proracyl; Germany: Propycil, Thyreostat; Greece: Propycil, Propylthiouracil, Prothuril; Hungary: Propycil; Luxembourg: Propylthiouracil; Netherlands: Propylthiouracil; Poland: Propycil, Thyrosan; Portugal: Propycil; Slovakia: Propycil; Slovenia: Propiltiouracil; Sweden: Tiotil; UK: Propylthiouracil.

North America

Canada: Propyl-Thyracil; USA: Propylthiouracil.

Latin America

Brazil: Propil, Propilracil.


Japan: Propacil, Thiuragyl.

Drug combinations


Propylthiouracil: C~7~H~10~N~2~OS. Mw: 170.23. (1) 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-; (2) 6-Propyl-2-thiouracil. CAS-51-52-5.

Pharmacologic Category

Antithyroid Agents; Thioamide. (ATC-Code: H03BA02)

Mechanism of action

Inhibits synthesis of thyroid hormones by blocking oxidation of iodine in thyroid gland. Blocks synthesis of thyroxine and triiodothyronine.

Therapeutic use

Palliative treatment of hyperthyroidism in preparation for surgical treatment or radioactive iodine therapy. Management of thyrotoxic crisis.

Pregnancy and lactiation implications

Propylthiouracil crosses placenta and adverse events may occur in fetus following maternal use. Fetal thyroid function may be transiently suppressed. Thioamides are treatment of choice for hyperthyroidism during pregnancy. Enters breast milk.

Unlabeled use


Hypersensitivity to propylthiouracil or any component of the formulation. Breast-feeding.

Warnings and precautions

May cause hypoprothrombinemia and bleeding (use with particular caution in patients >40 years of age). May cause significant bone marrow depression (agranulocytosis). Aplastic anemia, thrombocytopenia, and leukopenia may also occur. Use with caution in patients receiving other drugs known to cause myelosuppression, particularly agranulocytosis. Thyroid hyperplasia or carcinoma may occur with prolonged usage. Associated with rare but severe dermatologic reactions. Discontinue in presence of unexplained fever. Rare, severe hepatic reactions (hepatic necrosis, hepatitis) may occur. Associated with a variety of autoimmune reactions (including lupus-like syndrome), glomerulonephritis and interstitial nephritis with acute renal failure, rare reports of interstitial pneumonitis, and rarely with development of ANCA-positive vasculitis or leukocytoclastic vasculitis.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart